1 / 63

Neuroblastoma

Neuroblastoma. Neuroblastoma. A tumor of postganglionic sympathetic neuroblasts The sympathetic chain extends from the neck to the sacrum The adrenal gland Neurotransmitter- Catecholamines. Neuroblastoma - Epidemiology. Most common extracranial solid tumor Incidence – 10/million per year

carina
Download Presentation

Neuroblastoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Neuroblastoma

  2. Neuroblastoma A tumor of postganglionic sympathetic neuroblasts The sympathetic chain extends from the neck to the sacrum The adrenal gland Neurotransmitter- Catecholamines

  3. Neuroblastoma - Epidemiology • Most common extracranial solid tumor • Incidence – 10/million per year • ~10% of pediatric tumors • Peak age – 2-3 years • >90% cases before 5 years • Mostly sporadic – rare genetic associations • Most common neonatal tumor

  4. Neuroblastoma - Genetics Mostly sporadic – rare (2%) genetic associations (NF1, Hirschsprung, congenital central hypoventilation syndrome) Mutations in ALK (tyrosine kinase) Environment??

  5. Neuroblastoma – Biology • Neuroblastoma is a tumor of undifferentiated (embryonal) neuroectodermal cells, derived from the neural crest • An aberration of normal differentiation • An abnormal response to normal neurotropic signals (TRK-A, NGF) • Spontaneous regression • Differentiation – Ganglioneuroma, ganglioneuroblastoma

  6. Neuroblastoma – Clinical features I • Tumor originates from sympathetic ganglia/adrenal gland • Lymphatic and hematogenous spread • Metastases to bone, liver, bone marrow, skin • Most patients present with advanced disease (40% of all patients, 55% of patients over 1 year)

  7. Neuroblastoma-Clinical features - II Abdominal mass (65%) Thoracic mass (Infants) Bone pain Fever Weight loss “Sick looking child”

  8. Neuroblastoma – Clinical Features - III • Lower limb paresis – 20 to spinal epidural tumor (4%) • Severe diarrhea 20 to secretion of VIP (vasoactive intestinal peptide) (4%) • Horner syndrome - patients with cervical or upper thoracic sympathetic ganglia (1.7%) • Hypertension, flushing, sweating (0.2%) • Raccoon eyes • Pallor, bleeding diathesis (Bone marrow involvement)

  9. Neuroblastoma Raccoon eyes

  10. Neuroblastoma – Clinical features - IV Opsoclonus-Myoclonus syndrome Acute cerebellar encephalopathy characterized by cerebellar ataxia, rapid and random eye movements (opsoclonus) and myoclonic jerks (2.8%) Good oncological but poor neurological outcome

  11. Laboratory Features • Catecholamines (Dopamine, epinephrine, VMA, HVA) • Serum markers - LDH, ferritin, NSE (Neuron specific enolase) • Blood count (BM involvement) • Coagulation (Liver involvement)

  12. Metabolism of Catecholamines

  13. Pathology • Small round blue cell tumor • Neuroblastic differentiation: From very undifferentiated to differentiated • Degree of anaplasia – Shimada index • Biological parameters

  14. Neuroblastoma biology II • N-MYC – Oncogene on chromosome 2 amplification – worse prognosis • DI (DNA Index= ploidy) – hyperdiploid – better outcome in infants • 1p deletion – putative tumor suppressor genes – worse prognosis • 17q gain – oncogene?

  15. N-Myc amplification • Amplification – A localized genomic change that results in increased dosage of a gene or genes affected • Homogeneously staining regions (HSR’s) - are areas on the native chromosome with multiple 100-200 kB copies of the region containing the amplified gene • Double minutes (DM) – Extrachromosomal fragments containing the amplified gene • >10 copies are associated with a worse prognosis

  16. Mechanisms of N-myc amplification

  17. N-MYC amplification- Homogeneously staining region

  18. N-MYC amplification- Double minutes

  19. Neuroblastoma- 1p deletion

  20. Neuroblastoma - Staging • CT/MRI • MIBG (Meta-iodo-benzyl-guanidine) • Bone scan • Bone marrow aspirate and biopsy • Surgery

  21. MIBG scan

  22. Neuroblastoma - Staging

  23. Neuroblastoma - INSS Staging System Stage 1- Localized tumor with complete gross excision, with or without microscopic residual disease; representative ipsilateral lymph nodes negative for tumor microscopically (nodes attached to and removed with the primary tumor may be positive) Stage 2A – Localized tumor with incomplete gross resection; representative ipsilateral non-adherent lymph nodes negative for tumor microscopically Stage 2B- Localized tumor with or without complete gross excision, with ipsilateral non-adherent lymph nodes positive for tumor’ enlarged contralateral lymph nodes must be negative microscopically Stage 3 – Unresectable unilateral tumor infiltrating across the midline, with or without regional lymph node involvement; or localized unilateral tumor with contralateral regional lymph node involvement; or midline tumor with bilateral extension by infiltration (unresectable) or by lymph node involvement Stage 4 – Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin, and/or other organs (except as defined for stage 4s) Stage 4s – Localized primary tumor (as defined for stage 1, 2A or 2B) with dissemination limited skin, liver, and or bone marrow (limited to infants<1 year)

  24. 2b 4 1 2a 3 4S International Neuroblastoma Staging System (INSS)

  25. Prognostic Factors Age (<18m – favorable) Stage Histology (Shimada) Biology N-MYC, DI, 17q+, 1p-

  26. Neuroblastoma - Treatment Risk adapted Low risk NB – Minimal therapy – excellent outcome High NB – Intensive therapy – poor outcome

  27. INRG – International Neuroblastoma Risk Group Classification System Age Stage N-MYC status

  28. Neuroblastoma -Protocol assignment by risk group

  29. Low/Intermediate risk Neuroblastoma Watch and wait (No treatment=no toxicity) Surgery- Minimize damage Low intensity chemotherapy Radiation – emergency only (rarely used)

  30. Improving Survival for Stage 4 Neuroblastoma Patients > 1 Year of Age at Diagnosis 1 0.8 Childrens Cancer Group Data Probability of Overall Survival 0.6 0.4 1986-1995 N = 675 0.2 1978-1985 N = 507 P < 0.001 0 1 2 3 4 5 6 7 8 9 10 Years from Diagnosis

  31. Treatment – High Risk Neuroblastoma Induction chemotherapy Surgery High dose chemotherapy with stem cell rescue (Eradication of residual disease) Radiation Retinoic Acid Immunotherapy

  32. High-risk Neuroblastoma – Treatment Roadmap ████████████ ██ ██ Induction Surgery Consolidation XRT Cis-RA Immunorx. Chemotherapy ABMTAnti GD2 IL-2 GM-CSF (Differentiation therapy) Immunotherapy

  33. Chemotherapy in Neuroblastoma Platinum (Cis, carbo) VP-16 Doxorubicin Cyclophosphamide/Ifosfamide Vincristine Topotecan

  34. High Dose Chemotherapy Myeloablative doses Eradication of tumor Rescue with autologous stem cells MEC (Melphalan, etoposide, carboplatinum) BM (Busulfan, Melphalan)

  35. Neuroblastoma – Radiation Therapy • Local consolidation (In high-risk disease) • Massive hepatomegaly in infants with 4S • Cord compression? • Metastatic disease - palliation

  36. Neuroblastoma – Differentiation therapy • Cis-retinoic acid (Roaccutane) • Induces differentiation of neuroblastoma cells in vitro and decreases proliferative capacity • Shown in randomized clinical trial to improve outcome

  37. High-Dose, Pulse Retinoic Acid Induces Neuroblastoma Differentiation Control 10 mM Retinoic Acid

  38. Neuroblastoma – Immunotherapy Anti GD-2 antibodies Interleukin 2 GM-CSF

  39. Accrual of 386 randomized patients needed

  40. COG-ANBL0032 Phase III 2/17/09 Status: DATA AND SAFETY MONITORING COMMITTEE With ~61 % of accrual in, and ~ 2 year median follow up, the Immunotherapy arm shows: Superior EFS (p = 0.0115) Superior OS (p = 0.0223)

More Related